Cargando…

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability

The RV144 vaccine trial resulted in a decreased risk of HIV acquisition that was associated with a nonneutralizing antibody response. The objective of this study was to determine the impact of an additional boost to the RV144 vaccine regimen on antibody effector function and durability. DESIGN: RV30...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shubin, Zhanna, Stanfield-Oakley, Sherry, Puangkaew, Jiraporn, Pitisutthithum, Punnee, Nitayaphan, Sorachai, Gurunathan, Sanjay, Sinangil, Faruk, Chariyalertsak, Suwat, Phanuphak, Nittaya, Ake, Julie A., O’Connell, Robert J., Vasan, Sandhya, Akapirat, Siriwat, Eller, Michael A., Ferrari, Guido, Paquin-Proulx, Dominic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Basic Science: Concise Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355803/ https://www.ncbi.nlm.nih.gov/pubmed/37260254 http://dx.doi.org/10.1097/QAD.0000000000003611

Ejemplares similares

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
por: Costanzo, Margaret C., et al.
Publicado: (2023)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
por: Fischinger, Stephanie, et al.
Publicado: (2020)

RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2020)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2021)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
por: Choi, Ickwon, et al.
Publicado: (2015)

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144
por: Perez, Lautaro G., et al.
Publicado: (2017)

RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
por: Lewitus, Eric, et al.
Publicado: (2021)

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012)

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
por: Edlefsen, Paul T., et al.
Publicado: (2015)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
por: Nicely, Nathan I., et al.
Publicado: (2015)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand
por: Wansom, Tanyaporn, et al.
Publicado: (2021)

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants
por: Dommaraju, Kalpana, et al.
Publicado: (2014)

Fcgbp – A Potential Viral Trap in RV144
por: Schwartz, Jacquelyn L
Publicado: (2014)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
por: McLellan, JS, et al.
Publicado: (2012)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

HIV pre-exposure prophylaxis and health and community systems in the Global South: Thailand case study
por: Colby, Donn, et al.
Publicado: (2015)

Molecular epidemiology of the protective RV144 V2 loop epitope
por: Cardozo, T
Publicado: (2012)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
por: Yu, B, et al.
Publicado: (2012)

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
por: Williams, LaTonya D., et al.
Publicado: (2023)

Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
por: Shangguan, Shida, et al.
Publicado: (2021)

Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand
por: Crowell, Trevor A., et al.
Publicado: (2022)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
por: Easterhoff, David, et al.
Publicado: (2017)

HIV vaccines: progress and promise
por: Johnston, Margaret I., et al.
Publicado: (2021)

Longitudinal Analysis of Peripheral and Colonic CD161(+) CD4(+) T Cell Dysfunction in Acute HIV-1 Infection and Effects of Early Treatment Initiation
por: Lal, Kerri G., et al.
Publicado: (2020)

Correction: Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
Publicado: (2016)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial
por: Hertz, T, et al.
Publicado: (2012)

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok
por: Kroon, Eugène D.M.B., et al.
Publicado: (2017)

Application technology to fight the COVID-19 pandemic: Lessons learned in Thailand
por: Intawong, Kannikar, et al.
Publicado: (2021)

Application technology to fight the COVID-19 pandemic: Lessons learned in Thailand
por: Intawong, Kannikar, et al.
Publicado: (2021)

Antibodies to the envelope protein protect macaques from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial
por: Franchini, G, et al.
Publicado: (2012)

History of the prevention of mother-to-child transmission of HIV in Thailand
por: Phanuphak, Nittaya, et al.
Publicado: (2016)

Determinants of suboptimal CD4(+) T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV‐1 infection
por: Handoko, Ryan, et al.
Publicado: (2020)

Distinct mucosal and systemic immunological characteristics in transgender women potentially relating to HIV acquisition
por: Schuetz, Alexandra, et al.
Publicado: (2023)

A comparison of attitudes and knowledge of pre-exposure prophylaxis (PrEP) between hospital and Key Population Led Health Service providers: Lessons for Thailand’s Universal Health Coverage implementation
por: Rayanakorn, Ajaree, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sa5u6afgadm7vpgro6kp2albh4